Search our Database of Scientific Publications and Authors

I’m looking for a
    Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.
    Cochrane Database Syst Rev 2011 May 11(5):CD008214. Epub 2011 May 11.
    Sunderland Eye Infirmary, Queen Alexandra Road, Sunderland, UK, SR2 9HP.
    Background: Postoperative vitreous cavity haemorrhage (POVCH) is a significant complication following vitrectomy for proliferative diabetic retinopathy (PDR). It delays visual recovery and can make further treatment difficult if the view of the fundus is significantly obscured. A number of interventions to reduce the incidence of POVCH have been proposed, including the perioperative use of anti-vascular endothelial growth factor (anti-VEGF). Anti-VEGFs reduce vascular proliferation and the vascularity of neovascular tissue, which is often the source of bleeding following vitrectomy.

    Objectives: The review aims to assess the effect of perioperative anti-VEGF in reducing the incidence of POVCH.

    Search Strategy: We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2011, Issue 2), MEDLINE (January 1950 to March 2011), PubMed (10 March 2011), EMBASE (January 1980 to March 2011), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to March 2011), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com) and ClinicalTrials.gov (www.clinicaltrial.gov). There were no date or language restrictions in the electronic searches for trials. The electronic databases were last searched on 10 March 2011.

    Selection Criteria: We included all randomised controlled trials (RCTs) that looked at the use of anti-VEGFs and the incidence of POVCH in people undergoing vitrectomy for PDR.

    Data Collection And Analysis: Both review authors independently assessed and extracted the data using a standardised form based on the CONSORT statement.

    Main Results: We included four studies (202 eyes of 198 participants) in this review. The four RCTs met the inclusion criteria, but we were unable to conduct a meta-analysis due to methodological issues in three of the trials. We have provided a summary of the effects of the interventions. We have also provided a summary of the current literature addressing each primary and secondary outcome.

    Authors' Conclusions: Results from one of the included studies support the use of preoperative intravitreal bevacizumab to reduce the incidence of early POVCH. There are currently no other high quality RCTs that support the use of anti-VEGF agents perioperatively to reduce the incidence of early or late POVCH. The remaining studies identified by the search suggest that the preoperative use of bevacizumab may reduce the incidence of early POVCH, but it should be recognised that there are a number of significant methodological issues in these studies that lead us to be cautious when interpreting their findings and make any definitive conclusions unwarranted.

    Similar Publications

    Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.
    Cochrane Database Syst Rev 2015 Aug 7(8):CD008214. Epub 2015 Aug 7.
    Sunderland Eye Infirmary, Queen Alexandra Road, Sunderland, UK, SR2 9HP.
    Background: Postoperative vitreous cavity haemorrhage (POVCH) is a significant complication following vitrectomy for proliferative diabetic retinopathy (PDR). It delays visual recovery and can make further treatment difficult if the view of the fundus is significantly obscured. A number of interventions to reduce the incidence of POVCH have been proposed, including the perioperative use of anti-vascular endothelial growth factor (anti-VEGF). Read More
    Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.
    Cochrane Database Syst Rev 2014 Nov 24(11):CD008721. Epub 2014 Nov 24.
    Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), CIBER Epidemiología y Salud Pública (CIBERESP), Sant Antoni M. Claret 171, Casa de Convalescència, Barcelona, Catalonia, Spain, 08041.
    Background: Proliferative diabetic retinopathy (PDR) is a complication of diabetic retinopathy that can cause blindness. Although panretinal photocoagulation (PRP) is the treatment of choice for PDR, it has secondary effects that can affect vision. An alternative treatment such as anti-vascular endothelial growth factor (anti-VEGF), which produces an inhibition of vascular proliferation, could improve the vision of people with PDR. Read More
    Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Cochrane Database Syst Rev 2014 Aug 29(8):CD005139. Epub 2014 Aug 29.
    Wilmer Eye Institute, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Maumenee 740, Baltimore, Maryland, USA, 21287.
    Background: Age-related macular degeneration (AMD) is the most common cause of uncorrectable severe vision loss in people aged 55 years and older in the developed world. Choroidal neovascularization (CNV) secondary to neovascular AMD accounts for most AMD-related severe vision loss. Anti-vascular endothelial growth factor (anti-VEGF) agents, injected intravitreally, aim to block the growth of abnormal blood vessels in the eye to prevent vision loss and, in some instances, improve vision. Read More
    Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Cochrane Database Syst Rev 2013 Jan 31(1):CD009510. Epub 2013 Jan 31.
    Moorfields Eye Hospital NHS Foundation Trust, London,
    Background: Branch retinal vein occlusion (BRVO) is one of the most common occurring retinal vascular abnormalities. The pathogenesis of BRVO is thought to involve both retinal vein compression and damage to the vessel wall, possibly leading to thrombus formation at sites where retinal arterioles cross retinal veins. The most common cause of visual loss in patients with BRVO is macular oedema (MO). Read More